Science Doesn’t Stop!
By Jennifer C. King, PhD, Chief Scientific Officer I’m an optimist at heart -- to the point where my tween daughter just rolls her eyes at me whenever I tell her to have a more positive attitude. Consequently, while [...]
First FDA Approval of Combined Immunotherapy Treatment for NSCLC
On May 15, 2020, the Food and Drug Administration (FDA) approved the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for treatment of advanced non-small cell lung cancer (NSCLC) with a PD-L1 level equal to or greater than 1% for [...]
FDA Approves Retevmo (selpercatinib) for Treatment of Advanced NSCLC
On May 8, 2020, the Food and Drug Administration (FDA) approved Retevmo (selpercatinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in RET under the accelerated approval pathway. The FDA based their approval on the [...]
FDA Approves New First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
On March 27, 2020, the Food and Drug Administration (FDA) approved Imfinzi (durvalumab) in combination with etoposide and either carboplatin or cisplatin as first line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). The FDA based their [...]